We are live on
!
Find out more
Zurich Cantonal Bank Portfolio holdings
AUM
$52.2B
1-Year Est. Return
40.82%
This Fund
S&P 500
This Quarter
Est. Return
+25.92%
1 Year Est. Return
+40.82%
3 Year Est. Return
+127.89%
5 Year Est. Return
+169.31%
10 Year Est. Return
+639.41%
AUM
$52.2B
AUM Growth
+$6.23B
(+14%)
Cap. Flow
-$738M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
33.24%
Holding
2,615
New
60
Increased
1,027
Reduced
660
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$235M |
| 2 |
Morgan Stanley
MS
|
+$146M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$116M |
| 4 |
Micron Technology
MU
|
+$115M |
| 5 |
ExxonMobil
XOM
|
+$86.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$335M |
| 2 |
Intel
INTC
|
+$166M |
| 3 |
NVIDIA
NVDA
|
+$143M |
| 4 |
JPMorgan Chase
JPM
|
+$141M |
| 5 |
KLA
KLAC
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.28% |
| 2 | Financials | 16.42% |
| 3 | Healthcare | 10.64% |
| 4 | Industrials | 9.13% |
| 5 | Consumer Discretionary | 8.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DEFT
2401
Defi Technologies
DEFT
$229M
| $32.3K | ﹤0.01% |
59,555
-52,797
| -47% | -$35.8K |
|
|
SION
2402
Sionna Therapeutics
SION
$279M
| $31.2K | ﹤0.01% |
709
+338
| +91% | +$13.5K |
|
|
ALX
2403
Alexander's
ALX
$1.39B
| $29.8K | ﹤0.01% |
108
| – | – |
|
2404
GlobalFoundries
GFS
$25.1B
| $29.5K | ﹤0.01% |
358
| – | – |
|
2405
SOPHiA GENETICS
SOPH
$726M
| $29.5K | ﹤0.01% |
5,112
+1,357
| +36% | +$6.88K |
|
2406
Kyverna Therapeutics
KYTX
$532M
| $27.7K | ﹤0.01% |
3,113
+1,484
| +91% | +$13.2K |
|
2407
Enanta Pharmaceuticals
ENTA
$412M
| $27K | ﹤0.01% |
1,853
+947
| +105% | +$12.7K |
|
|
ABVX
2408
Abivax
ABVX
$10.2B
| $26.4K | ﹤0.01% |
198
+93
| +89% | +$10.5K |
|
2409
Rigel Pharmaceuticals
RIGL
$868M
| $24.7K | ﹤0.01% |
632
+297
| +89% | +$9.16K |
|
2410
Ironwood Pharmaceuticals
IRWD
$709M
| $24.5K | ﹤0.01% |
5,827
+2,748
| +89% | +$10.6K |
|
|
ESPR
2411
DELISTED
Esperion Therapeutics
ESPR
| $23.6K | ﹤0.01% |
7,455
+3,591
| +93% | +$10K |
|
2412
BlueLinx
BXC
$651M
| $23.2K | ﹤0.01% |
375
-1,180
| -76% | -$63.8K |
|
2413
Structure Therapeutics
GPCR
$3.52B
| $20.7K | ﹤0.01% |
385
+173
| +82% | +$7.65K |
|
2414
Entrada Therapeutics
TRDA
$273M
| $19.8K | ﹤0.01% |
2,688
+1,271
| +90% | +$12.2K |
|
|
MAZE
2415
Maze Therapeutics
MAZE
$1.64B
| $19.5K | ﹤0.01% |
655
+294
| +81% | +$7.71K |
|
2416
Vanda Pharmaceuticals
VNDA
$323M
| $19.3K | ﹤0.01% |
3,161
+1,418
| +81% | +$9.26K |
|
2417
Pacific Biosciences
PACB
$485M
| $15.4K | ﹤0.01% |
9,146
| – | – |
|
2418
Keros Therapeutics
KROS
$220M
| $15.1K | ﹤0.01% |
1,415
+716
| +102% | +$7.98K |
|
2419
Rani Therapeutics
RANI
$97.1M
| $14.5K | ﹤0.01% |
19,051
+8,549
| +81% | +$7.58K |
|
2420
Zegna
ZGN
$3.68B
| $13.7K | ﹤0.01% |
1,049
| – | – |
|
2421
Lexeo Therapeutics
LXEO
$411M
| $12.8K | ﹤0.01% |
2,742
+1,387
| +102% | +$7.5K |
|
2422
Lyell Immunopharma
LYEL
$363M
| $12.7K | ﹤0.01% |
905
+458
| +102% | +$8.29K |
|
2423
Rocket Pharmaceuticals
RCKT
$402M
| $12.2K | ﹤0.01% |
3,557
| – | – |
|
2424
Myriad Genetics
MYGN
$298M
| $11.7K | ﹤0.01% |
2,044
-37,658
| -95% | -$171K |
|
|
JKS
2425
JinkoSolar
JKS
$715M
| $11.5K | ﹤0.01% |
683
| – | – |
|
Similar funds
DB
Zurich Cantonal Bank's Q2 2026 Portfolio in Review
As of Q2 2026, Zurich Cantonal Bank held 2,615 positions worth $52.2B, up 14% from $46B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Trading was light in Q2 2026: portfolio turnover was 4.8%. Zurich Cantonal Bank opened 60 new positions and exited 66, leaving the 2,615-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 30% a quarter earlier, followed by Financials and Healthcare.
- Zurich Cantonal Bank's largest Q2 2026 buy was State Street SPDR S&P Global Natural Resources ETF: 431,270 shares worth $28.9M.
- Zurich Cantonal Bank added most to Advanced Micro Devices in Q2 2026, an estimated $235M increase.
- Zurich Cantonal Bank's biggest Q2 2026 reduction was Microsoft, cutting an estimated $335M.
- Zurich Cantonal Bank fully exited Hologic in Q2 2026, selling an estimated $9.61M.
- Zurich Cantonal Bank's ten largest holdings make up 33% of its $52.2B portfolio in Q2 2026.
- Zurich Cantonal Bank opened 60 new positions and closed 66 in Q2 2026.
- Zurich Cantonal Bank's portfolio value rose 14% quarter-over-quarter to $52.2B.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.